FDA Approves Blujepa for Uncomplicated Urinary Tract Infections

Follow Drugslib on

Medically reviewed by Drugs.com.

By Stephanie Brown HealthDay Reporter

TUESDAY, March 25, 2025 -- The U.S. Food and Drug Administration has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women (weighing 40 kg or more) and children (12 years and older; weighing 40 kg or more).

Blujepa, a first-in-class oral antibiotic, is approved for treatment of uUTIs caused by Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus, and Enterococcus faecalis.

The approval of Blujepa was based on results from the phase 3 EAGLE-2 and EAGLE-3 trials, which demonstrated the medication's noninferiority and superiority, respectively, to nitrofurantoin (one of the leading current standard-of-care options for uUTI) in women and pediatric patients (aged 12 years and older) with a confirmed uUTI.

In EAGLE-2, therapeutic success occurred in 50.6 percent of patients taking Blujepa compared with 47.0 percent of those taking nitrofurantoin. In EAGLE-3, statistically significant superiority was demonstrated for Blujepa versus nitrofurantoin, with therapeutic success occurring in 58.5 versus 43.6 percent.

The most commonly reported adverse events in patients taking Blujepa were gastrointestinal, including diarrhea (16 percent) and nausea (9 percent). The maximum severity of these adverse events was mostly mild (69 percent) and moderate (28 percent). Severe gastrointestinal events occurred in less than 1 percent of all participants. Across both trials, there was one drug-related serious adverse event reported in each treatment arm (Blujepa and nitrofurantoin).

"The approval of Blujepa is a crucial milestone, with uUTIs among the most common infections in women," Tony Wood, chief scientific officer of GSK, said in a statement. "We are proud to have developed Blujepa, the first in a new class of oral antibiotics for uUTIs in nearly three decades, and to bring another option to patients given recurrent infections and rising rates of resistance to existing treatments."

The approval of Blujepa was granted to GlaxoSmithKline.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-03-26 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords